Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 20.04.2026 1 Am J Clin Pathol 2 Am J Surg 1 Am J Surg Pathol 14 Ann Surg Oncol 6 BMC Cancer 2 Br J Cancer 3 Breast Cancer 5 Breast Cancer (Dove Med Press) 7 Breast Cancer Res 13 Breast Cancer Res Treat 1 Breast J 1 Cancer 4 Cancer Lett 1 Cancer Res 14 Clin Breast Cancer 2 Clin Cancer Res 2 Eur J Cancer 1 Eur J Surg Oncol 5 Eur Radiol 2 Int J Cancer 1 J Clin Oncol 2 N Engl J Med 1 Nature 3 NPJ Breast Cancer 4 Oncogene 1 Oncol Rep 3 PLoS One 4 Proc Natl Acad Sci U S A 1 Radiology 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. THABIT DM
   Immunohistochemical expression of POC1A, NUF2, and Ki-67 in invasive ductal carcinoma of the breast: prognostic significance with insights into triple-negative breast cancer.
   Am J Clin Pathol. 2026;165:aqag011.
   PubMed        
   
   

   
   Am J Surg

2. POH DHX, Tan CLY, Ng Y, Zhou KX, et al
   Active surveillance for low-grade ductal carcinoma in situ: A mixed-methods systematic review of patient, clinician, and health-system perspectives.
   Am J Surg. 2026;256:116898.
   PubMed         Abstract available
   
   
3. MOKBEL K, Mokbel K
   Axillary lymph node dissection is not routinely indicated in patients with sentinel lymph node residual micrometastases following neoadjuvant systemic therapy.
   Am J Surg. 2026;256:116901.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

4. HAW Y, Krings G, Hsiao WY, Zhan H, et al
   Clinicopathologic Analyses of 34 Cases of High-Grade Serous-Like Carcinoma (HG-SL-Ca) of the Breast.
   Am J Surg Pathol. 2026;50:543-549.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. LEE YR, Giannakeas V, Narod SA, Lim DW, et al
   ASO Visual Abstract: Association Between Tumor Size and Nodal Positivity for HER2+ and Triple-Negative Early-Stage Breast Cancer: A Population-Based Study.
   Ann Surg Oncol. 2026 Apr 17. doi: 10.1245/s10434-026-19659.
   PubMed        
   
   
6. WANG J, Chen J, Amburn T, Wagner BD, et al
   ASO Visual Abstract: Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema.
   Ann Surg Oncol. 2026 Apr 17. doi: 10.1245/s10434-026-19367.
   PubMed        
   
   
7. SHERN TP, Holt LR, Lloyd K, Daly AE, et al
   ASO Visual Abstract: Economic and Health System Impact of Implementing the SOUND Trial Approach in Early-Stage Breast Cancer.
   Ann Surg Oncol. 2026 Apr 16. doi: 10.1245/s10434-026-19657.
   PubMed        
   
   
8. SHAH A, Love JA, Butler M, Butler LN, et al
   ASO Visual Abstract: Integrating Generative AI into Nomograms for Breast Cancer Nodal Risk Predictions.
   Ann Surg Oncol. 2026 Apr 15. doi: 10.1245/s10434-026-19605.
   PubMed        
   
   
9. CHIDA K, Wu R, Kawashima K, Grapes A, et al
   Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2- Breast Cancer.
   Ann Surg Oncol. 2026 Apr 10. doi: 10.1245/s10434-026-19620.
   PubMed         Abstract available
   
   
10. HANNOUN-LEVI JM, Kirova Y
    Re-irradiation for Second Ipsilateral Breast Cancer Event: Is There Any Debate?
    Ann Surg Oncol. 2026 Apr 10. doi: 10.1245/s10434-026-19584.
    PubMed        
    
    
11. SIDIROPOULOU Z
    The Superficial (Anterior) Plane in Mastectomy: An Under-Measured Margin Variable with Implications for Local Recurrence.
    Ann Surg Oncol. 2026;33:4648-4649.
    PubMed         Abstract available
    
    
12. LLOYD K, Shern TP, Holt LR, Daly AE, et al
    Outpatient Mastectomy with Reconstruction at Ambulatory Surgery Centers.
    Ann Surg Oncol. 2026;33:4573-4583.
    PubMed         Abstract available
    
    
13. CHANDRAN T, Wager JL, Obeid K, Baker J, et al
    Does Multidisciplinary Clinic Impact Rates of Breast Conserving Therapy?
    Ann Surg Oncol. 2026;33:4555-4562.
    PubMed         Abstract available
    
    
14. CUILLERIER NJS, Almarzooqi H, Villareal-Corpuz V, Sabboobeh S, et al
    Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.
    Ann Surg Oncol. 2026;33:4510-4517.
    PubMed         Abstract available
    
    
15. HOLT L, Chamberlain V, Shern T, Abir FF, et al
    AI-FLEET: Phase I-Multimodal Deep Learning Model for Phyllodes Tumor Classification.
    Ann Surg Oncol. 2026;33:4503-4509.
    PubMed         Abstract available
    
    
16. TAYLOR ND, Rezo A, Majeed U, He YM, et al
    Impact of Anterior Margin Status Following Skin- or Nipple-Sparing Mastectomy in Patients Undergoing Implant-Based Breast Reconstruction.
    Ann Surg Oncol. 2026;33:4494-4502.
    PubMed         Abstract available
    
    
17. MASANAM MK, Kantor O, Pappas Brunco O, Faust AC, et al
    Evaluating the Impact of a Surgeon-Led Ductal Carcinoma in Situ Program on Endocrine Therapy Uptake.
    Ann Surg Oncol. 2026;33:4463-4471.
    PubMed         Abstract available
    
    
18. GARCIA DI, Daly AE, Anderman KJ, Holt LR, et al
    Bracketed Lumpectomy: A Comparison of Radiofrequency Identification Tag Localization to Wire Localization.
    Ann Surg Oncol. 2026;33:4407-4416.
    PubMed         Abstract available
    
    

    
    BMC Cancer

19. NASCIMENTO DW, Filassi JR, Cunha AFT, Goncalves R, et al
    Impact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil.
    BMC Cancer. 2026 Apr 16. doi: 10.1186/s12885-026-15994.
    PubMed        
    
    
20. LIU Y, He T, Tang C, Li F, et al
    Single-cell and spatial transcriptome analysis of breast cancer tumor-associated fibroblast heterogeneity and its mediated remodeling of the tumor microenvironment.
    BMC Cancer. 2026 Apr 15. doi: 10.1186/s12885-026-16003.
    PubMed        
    
    
21. WIJAYALATHGE H, Peiris K, Jayarajah U, Gunasekara S, et al
    Quality of life following completion of surgery and chemoradiation among Sri Lankan women with breast cancer.
    BMC Cancer. 2026 Apr 13. doi: 10.1186/s12885-026-15991.
    PubMed        
    
    
22. CONG B, Hou C, Shan C, Sun S, et al
    Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15983.
    PubMed        
    
    
23. KOCHI A, Kashiwagi S, Nakada K, Gose A, et al
    Clinical impact of the 21-gene recurrence score on adjuvant treatment selection in elderly patients with hormone receptor-positive, HER2-negative early breast cancer.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15948.
    PubMed        
    
    
24. WALBAUM B, Acevedo F, Segui E, Martinez-Saez O, et al
    Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.
    BMC Cancer. 2026 Apr 10. doi: 10.1186/s12885-026-15998.
    PubMed        
    
    

    
    Br J Cancer

25. WANG DY, Jiang Z, Ben-David Y, Done SJ, et al
    TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression.
    Br J Cancer. 2026 Apr 16. doi: 10.1038/s41416-026-03419.
    PubMed         Abstract available
    
    
26. XIE X, Lee J, Gi YJ, Poullikkas T, et al
    ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
    Br J Cancer. 2026 Apr 15. doi: 10.1038/s41416-026-03413.
    PubMed         Abstract available
    
    

    
    Breast Cancer

27. TANAKA K, Shimomura A, Ishitobi M, Yamanaka T, et al
    Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.
    Breast Cancer. 2026 Apr 16. doi: 10.1007/s12282-026-01846.
    PubMed        
    
    
28. SAKAI H, Kusumoto-Matsuo R, Hosonaga M, Nozawa K, et al
    BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).
    Breast Cancer. 2026 Apr 10. doi: 10.1007/s12282-026-01855.
    PubMed        
    
    
29. HAMBURGER ECB, Garakani MM, Ghazizadeh S, Alfaisali S, et al
    Targeting breast cancer senescence in 3D models of bone metastasis.
    Breast Cancer. 2026 Apr 10. doi: 10.1007/s12282-026-01857.
    PubMed        
    
    

    
    Breast Cancer (Dove Med Press)

30. SHARAF B, Seif A, Bani Hani H, Alhasan M, et al
    Bridging Clinical Trials to Real-World Clinical Practice: TCHP Neoadjuvant Therapy Outcomes in HER2-Positive Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:559555.
    PubMed         Abstract available
    
    
31. MA S, Huang Y, Yang Q, Liu X, et al
    Analysis of Factors Related to Lymph Node Metastasis Following Neoadjuvant Chemotherapy for Breast Cancer: Correlation Between Plasma Exosomal Circular RNA and Metastasis.
    Breast Cancer (Dove Med Press). 2026;18:588196.
    PubMed         Abstract available
    
    
32. WU J, Yi W, Liu M, Li Y, et al
    IFI44 Orchestrates an IL-10-Driven M2 Macrophage Program in Breast Cancer: An Immune Prognostic Signature.
    Breast Cancer (Dove Med Press). 2026;18:579301.
    PubMed         Abstract available
    
    
33. ZHANG Q, Wang S, Zhang J, Chu T, et al
    Supportive Intervention for Unmet Needs Among Breast Cancer Patients and Their Spousal Caregivers: A Randomized Controlled Trial.
    Breast Cancer (Dove Med Press). 2026;18:585827.
    PubMed         Abstract available
    
    
34. OZDEMIR K, Muhtaroglu A, Kamburoglu MB, Guney Eskiler G, et al
    Peripheral Blood IL-6 and STAT3 Gene Expression as Biomarkers Associated with Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer: A Prospective Cross-Sectional Study.
    Breast Cancer (Dove Med Press). 2026;18:593138.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

35. LONNING PE, Nikolaienko O, Knappskog S
    Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle.
    Breast Cancer Res. 2026 Apr 17. doi: 10.1186/s13058-026-02279.
    PubMed        
    
    
36. SMITH SJ, Gibson C, Moorin R, Newton J, et al
    "Hurtled down a track and then thrown off": experiences of longitudinal breast cancer care trajectories of women living with and beyond breast cancer.
    Breast Cancer Res. 2026 Apr 18. doi: 10.1186/s13058-026-02264.
    PubMed        
    
    
37. ZHAO X, Fan Y, Yang J, Gao H, et al
    Single-cell transcriptomics identify mechanical-memory-associated cell states in metastatic HR(+) breast cancer.
    Breast Cancer Res. 2026 Apr 17. doi: 10.1186/s13058-026-02280.
    PubMed        
    
    
38. LIU L, Gao Y, Yu D, Li D, et al
    TFRC promotes ferroptosis to suppress breast cancer bone metastasis via the activation of HIF-1 pathway.
    Breast Cancer Res. 2026 Apr 15. doi: 10.1186/s13058-026-02269.
    PubMed        
    
    
39. KLAUS FL, Kitzke I, Klein E, Mogler C, et al
    MUCL1 in triple-negative breast cancer: a novel marker associated with the luminal androgen receptor subtype.
    Breast Cancer Res. 2026;28:73.
    PubMed         Abstract available
    
    
40. YOSHIDA T, Wei F, Kouro T, Kawaguchi K, et al
    Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.
    Breast Cancer Res. 2026 Apr 15. doi: 10.1186/s13058-026-02259.
    PubMed        
    
    
41. ZOPF EM, Joernaker G, Clauss D, Trevaskis M, et al
    Exercise effects on lean body mass, muscle strength and functional performance in patients with metastatic breast cancer: the randomized controlled PREFERABLE-EFFECT study.
    Breast Cancer Res. 2026 Apr 13. doi: 10.1186/s13058-026-02235.
    PubMed        
    
    

    
    Breast Cancer Res Treat

42. VERHEUL EM, Doornkamp F, Petrov I, Siesling S, et al
    External validation of PREDICT Breast v3.1 for overall survival in international cohorts, including young and invasive lobular subgroups.
    Breast Cancer Res Treat. 2026;217:14.
    PubMed         Abstract available
    
    
43. RODRIGUES LLC, de Holanda Juca Silveira L, de Almeida LFC, de Freitas BG, et al
    Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2026;217:16.
    PubMed         Abstract available
    
    
44. TAM G, Waddell D, Freeman JQ, Chen N, et al
    Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis.
    Breast Cancer Res Treat. 2026;217:22.
    PubMed         Abstract available
    
    
45. MILLER PC, Sharma U, Tao J, Sun J, et al
    In vivo exposure to CXCL12-high CAFs and chronic CXCL12 stimulation in vitro is sufficient to enhance metastasis of ER-positive breast cancer.
    Breast Cancer Res Treat. 2026;217:21.
    PubMed         Abstract available
    
    
46. YI H, Zhong Y, Xing D, Wang Y, et al
    Black and White disparity in U.S. female breast cancer mortality: a nationwide analysis, 1999-2023.
    Breast Cancer Res Treat. 2026;217:15.
    PubMed         Abstract available
    
    
47. RAJPUT S, Vierkant RA, Olson KN, Larson NL, et al
    Factors associated with and patterns of alcohol intake in late survivorship for breast cancer survivors.
    Breast Cancer Res Treat. 2026;217:13.
    PubMed         Abstract available
    
    
48. WANG W, Liu M, Li X
    Single-cell RNA sequencing and Mendelian randomization identify context-dependent LIPA-associated classical monocyte states in sepsis and breast cancer.
    Breast Cancer Res Treat. 2026;217:18.
    PubMed         Abstract available
    
    
49. WANG DK, Steele JA, Opalenik SR, Balko JM, et al
    Topoisomerase I inhibitor antibody-drug conjugates in breast cancer: the relevance of the DNA damage response to resistance, response, and combination treatment strategies.
    Breast Cancer Res Treat. 2026;217:17.
    PubMed         Abstract available
    
    
50. JOHNSON HM, Tasoulis MK, Kuerer HM
    Eliminating breast cancer surgery in exceptional responders: selective omission - not blind omission.
    Breast Cancer Res Treat. 2026;217:24.
    PubMed        
    
    
51. KAROLINA A, Marcin E, Magdalena G, Mateusz D, et al
    Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients-a prospective study.
    Breast Cancer Res Treat. 2026;217:19.
    PubMed         Abstract available
    
    
52. MASLANA KE, Burns RD, Bai Y, Playdon MC, et al
    The association of an exercise and rehabilitation clinical workflow algorithm on sedentary behavior and performance status from time of breast cancer diagnosis and throughout care.
    Breast Cancer Res Treat. 2026;217:23.
    PubMed         Abstract available
    
    
53. KO G, Zhang E, Yee E, Hallet J, et al
    Provider level facilitators and barriers towards neoadjuvant chemotherapy for triple negative and HER2 + breast cancer: a survey of Ontario surgeons.
    Breast Cancer Res Treat. 2026;217:20.
    PubMed         Abstract available
    
    
54. LESHEM Y, Golomb I, Zubkov A, Bar Y, et al
    Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2026;217:12.
    PubMed         Abstract available
    
    

    
    Breast J

55. NATHANSON SD, Leonard-Murali S, Bui J, Chitale DA, et al
    Selected Pathological Criteria That Predict Low Rates of Axillary Lymph Node Metastases Regardless of Patient Age: A Single Institution Study.
    Breast J. 2026;2026:e6196988.
    PubMed         Abstract available
    
    

    
    Cancer

56. MILLER KD, Thomas A, Althouse S, Zang Y, et al
    A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.
    Cancer. 2026;132:e70407.
    PubMed         Abstract available
    
    

    
    Cancer Lett

57. ZHANG S, Shi Z, Du S, Zhu T, et al
    Integration of longitudinal MRI and biopsy whole slide images for early prediction of neoadjuvant therapy response and personalized management in breast cancer: A multicenter retrospective and prospective study.
    Cancer Lett. 2026;650:218508.
    PubMed         Abstract available
    
    
58. YING XH, Zhang KY, Jiang SH, Chen L, et al
    Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancer Patients.
    Cancer Lett. 2026 Apr 11:218503. doi: 10.1016/j.canlet.2026.218503.
    PubMed         Abstract available
    
    
59. HONG L, Lee S, Frisbie L, Zhao Y, et al
    Nitroalkenes Exploit Dependence on Autophagy-Lysosome Pathway in PARPi-Resistant Triple Negative Breast Cancer.
    Cancer Lett. 2026 Apr 11:218504. doi: 10.1016/j.canlet.2026.218504.
    PubMed         Abstract available
    
    
60. LEU JS, Deng H, Tran HN, Wei X, et al
    Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis.
    Cancer Lett. 2026;649:218491.
    PubMed         Abstract available
    
    

    
    Cancer Res

61. NANDI D, Parida S, Verma D, Foley JR, et al
    Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis.
    Cancer Res. 2026 Feb 16:10.1158/0008-5472.CAN-25-2086.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

62. SHIGEMATSU H, Sasada S, Amioka A, Hashizume J, et al
    Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study.
    Clin Breast Cancer. 2026;26:75-82.
    PubMed         Abstract available
    
    
63. KIM KH, Sohn J, Kim MH, Kim JH, et al
    Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer.
    Clin Breast Cancer. 2026 Mar 18:S1526-8209(26)00042.
    PubMed         Abstract available
    
    
64. LEONE JP, Sedrak MS
    Age and Sex in Breast Cancer: Moving Beyond a One-Size-Fits-All Approach.
    Clin Breast Cancer. 2026;26:71-74.
    PubMed         Abstract available
    
    
65. SURENDRAN AM, Rai A, Rakshit S, George M, et al
    Retraction notice to "Immunomodulatory Role of Diospyros peregrina Fruit Preparation in Breast Cancer by Utilizing Macrophage Mediated Antigen Presentation and T Helper Cell (Th) Differentiation" [Clinical Breast Cancer 23 (2023) e95-e102].
    Clin Breast Cancer. 2026;26:172.
    PubMed        
    
    
66. SYMONDS L, Swensen SN, Nguyen MH, Hippe DS, et al
    Concurrent Chemotherapy With Adjuvant Radiation for Patients With High-risk Locally Advanced Breast Cancer: Safety and Outcomes.
    Clin Breast Cancer. 2026;26:63-70.
    PubMed         Abstract available
    
    
67. TAY VKL, Lim GH, Tan VK, Tan BKT, et al
    Mammogram Surveillance Outcomes After Oncoplastic or Standard Breast Conserving Surgery in Asians-A Comparison Study Exploring the Effect of Breast Density.
    Clin Breast Cancer. 2026;26:99-108.
    PubMed         Abstract available
    
    
68. LI H, Wang Z
    Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Supporting Treatment De-Escalation.
    Clin Breast Cancer. 2026;26:150-157.
    PubMed         Abstract available
    
    
69. PAGANINI A, Karlsson SA, Westesson LM, Larsson C, et al
    Are Expectations in Breast Reconstruction Manageable? A Mixed-Methods GoBreast II Study on Women's Goals of Breast Reconstruction After Mastectomy.
    Clin Breast Cancer. 2026;26:58-66.
    PubMed         Abstract available
    
    
70. ILAN K, Mostafa J, Weidenfeld RF, Samoocha D, et al
    Identification of Breast Abnormalities Using Feminai-Breast Examination Patch: A Feasibility Study.
    Clin Breast Cancer. 2026;26:51-57.
    PubMed         Abstract available
    
    
71. CAZENAVE MG, Mahiou K, Elahi L, Maumy L, et al
    SENOPAUSE: Evaluation of an ASCO-Derived Clinical Proxy for Axillary Risk Stratification in a Retrospective Cohort.
    Clin Breast Cancer. 2026;26:37-43.
    PubMed         Abstract available
    
    
72. SOUSA R, Peleteiro B, Tavares N, Meireles P, et al
    What Would it be Like if the Results of the SOUND Trial Were Applied in Portugal?- A Speculative Analysis Based on Real-World Data.
    Clin Breast Cancer. 2026;26:25-36.
    PubMed         Abstract available
    
    
73. GOLASH A, Roshanlall C, Kokan J, Clay V, et al
    A Comparative Analysis of the Utility of Nottingham Prognostic Index and Ki-67 in Selecting ER-positive HER2-negative Patients for Oncotype DX Testing.
    Clin Breast Cancer. 2026;26:17-24.
    PubMed         Abstract available
    
    
74. WU J, Bao H, He Z, Xing Y, et al
    The Pedicled Lateral Thoracic Lymph-Adipofascial Flap: A Nonmicrosurgical Lymph-Interpositional Technique to Prevent Upper Limb Lymphedema After Axillary Lymph Node Dissection-Preliminary Outcomes.
    Clin Breast Cancer. 2026;26:1-7.
    PubMed         Abstract available
    
    
75. KNOEDLER SA, Schaschinger T, Niederegger T, Knoedler L, et al
    Microsurgery on Steroids: The Impact of Chronic Immunosuppressive Therapy on Outcomes Following Free Flap Breast Reconstruction.
    Clin Breast Cancer. 2026;26:128-136.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

76. DESMEDT C, Nguyen HL, Richard F, Linn S, et al
    Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.
    Clin Cancer Res. 2026 Apr 17. doi: 10.1158/1078-0432.CCR-25-3808.
    PubMed         Abstract available
    
    
77. THURSBY SJ, Jin Z, Blum J, Gurau A, et al
    Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.
    Clin Cancer Res. 2026;32:1528-1539.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

78. ZHANG X, Zhang S, Liu Y, Liu J, et al
    Retraction notice to "Effects of the combination of RAD001 and docetaxel on breast cancer stem cells" [Eur J Cancer 48 (2012) 1581-1592].
    Eur J Cancer. 2026 Apr 13:116733. doi: 10.1016/j.ejca.2026.116733.
    PubMed        
    
    
79. MANCUSO P, Ragazzi M, Castellano I, Iotti V, et al
    Histological subtype and receptor characteristics of cancers detected or missed by digital mammography and tomosynthesis: Results from MAITA randomized trials.
    Eur J Cancer. 2026;238:116687.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

80. ANDERSEN LS, Jensen K, Tvedskov THF
    Management of non-detection of the sentinel node in breast cancer: A scoping review.
    Eur J Surg Oncol. 2026;52:111790.
    PubMed         Abstract available
    
    

    
    Eur Radiol

81. WOO E, Lee JY, Seo BK, Bae MS, et al
    Diagnostic performance of shear-wave dispersion imaging and shear-wave elastography for differentiating benign and malignant breast masses.
    Eur Radiol. 2026;36:3378-3391.
    PubMed         Abstract available
    
    
82. NEETER LMFH, Lobbes MBI, Duvivier KM, Raat HPJF, et al
    Cost-effectiveness of contrast-enhanced mammography compared to conventional imaging in the work-up after screening (RACER trial).
    Eur Radiol. 2026;36:3396-3405.
    PubMed         Abstract available
    
    
83. APPELMAN L, Gil Quessep E, Veenendaal L, Siebers C, et al
    Contribution of mammographic imaging after initial ultrasound in women with focal breast complaints-systematic review.
    Eur Radiol. 2026;36:3346-3357.
    PubMed         Abstract available
    
    
84. HADIDCHI R, Agrawal A, Liu MZ, Maldijan T, et al
    A deep learning framework to stratify Nottingham histologic grade 2 breast tumors based on dynamic contrast-enhanced MRI.
    Eur Radiol. 2026;36:3335-3345.
    PubMed         Abstract available
    
    
85. SHENG W, Wang Y, Xiao L, Guo B, et al
    BI-RADS-compliant structured mammography reporting using locally deployed large language models under privacy constraints.
    Eur Radiol. 2026;36:3676-3686.
    PubMed         Abstract available
    
    

    
    Int J Cancer

86. MALCOMSON L, Brentnall A, Renehan AG, Pegington M, et al
    Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom).
    Int J Cancer. 2026 Apr 12. doi: 10.1002/ijc.70489.
    PubMed         Abstract available
    
    
87. ANDOUR L, Hagenaars SC, de Groot AF, Krol-Warmerdam EMM, et al
    The Predictive Value of the Tumor-Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer.
    Int J Cancer. 2026 Apr 10. doi: 10.1002/ijc.70490.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

88. KHOR S, Yu K, Fedorenko CR, Ramsey S, et al
    Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening.
    J Clin Oncol. 2026;44:1130-1138.
    PubMed         Abstract available
    
    

    
    N Engl J Med

89. TOLANEY SM, Schmid P
    Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2026;394:1554.
    PubMed        
    
    
90. XIAO L, Lin C
    Sacituzumab Govitecan for Triple-Negative Breast Cancer.
    N Engl J Med. 2026;394:1553.
    PubMed        
    
    

    
    Nature

91. JORDAN NV, Bardia A, Wittner BS, Benes C, et al
    Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.
    Nature. 2026 Apr 15. doi: 10.1038/s41586-026-10519.
    PubMed        
    
    

    
    NPJ Breast Cancer

92. TO B, Prasath V, Veney D, Rolfo C, et al
    Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Apr 16. doi: 10.1038/s41523-026-00953.
    PubMed         Abstract available
    
    
93. VAN MACKELENBERGH MT, Pfarr N, Weber K, Untch M, et al
    Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.
    NPJ Breast Cancer. 2026;12:59.
    PubMed         Abstract available
    
    
94. HORNER M, Hartkopf A, John N, Ziegler P, et al
    PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.
    NPJ Breast Cancer. 2026;12:60.
    PubMed         Abstract available
    
    

    
    Oncogene

95. ZHANG Y
    Methodological considerations for centromere copy number analyses in HER2-positive metastatic breast cancer.
    Oncogene. 2026 Apr 16. doi: 10.1038/s41388-026-03793.
    PubMed        
    
    
96. HU H, Zhang H, Xing Y, Zhou Y, et al
    Correction: The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.
    Oncogene. 2026 Apr 15. doi: 10.1038/s41388-026-03790.
    PubMed        
    
    
97. LI S, Gong Y, Li H, Liu S, et al
    CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer.
    Oncogene. 2026 Apr 15. doi: 10.1038/s41388-026-03786.
    PubMed         Abstract available
    
    
98. LV X, Han L, Tong WW, Sun X, et al
    Blocking ubiquitination of hnRNPA1 maintains the self-renewal of breast cancer stem cells via mutually exclusive splicing of PKM pre-mRNA.
    Oncogene. 2026 Apr 14. doi: 10.1038/s41388-026-03776.
    PubMed         Abstract available
    
    

    
    Oncol Rep

99. GUO ZJ, Yu Q, Sha R, Li W, et al
    PINK1?mediated mitophagy enhances breast cancer proliferation through metabolic reprogramming.
    Oncol Rep. 2026;55:112.
    PubMed         Abstract available
    
    

    
    PLoS One

100. WANG Y, Zou Z, Wu Y, Chen J, et al
     Multi-task adaptive deep sparse canonical correlation analysis for multi-omics cancer survival prediction.
     PLoS One. 2026;21:e0346274.
     PubMed         Abstract available
     
     
101. 
     Expression of Concern: Targeting necroptosis in MCF-7 breast cancer cells: In Silico insights into 8,12-dimethoxysanguinarine from Eomecon Chionantha through molecular docking, dynamics, DFT, and MEP studies.
     PLoS One. 2026;21:e0347090.
     PubMed        
     
     
102. RANI H, Mehmood T, Aslam M, Al-Essa LA, et al
     Unveiling the Multifaceted Dynamics of Breast Cancer: A Copula Regression Approach to Modeling and Predicting Outcomes.
     PLoS One. 2026;21:e0346495.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

103. FARIAS A, Bridgeman VL, Rodrigues FS, Puttur F, et al
     Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
     Proc Natl Acad Sci U S A. 2026;123:e2412919123.
     PubMed         Abstract available
     
     
104. WILLIAMS SCP
     Profile of Helen M. Piwnica-Worms.
     Proc Natl Acad Sci U S A. 2026;123:e2609807123.
     PubMed         Abstract available
     
     
105. OLSON AW, Li J, Li XY, King L, et al
     Amoeboid-mesenchymal transition and the proteolytic control of cancer invasion plasticity.
     Proc Natl Acad Sci U S A. 2026;123:e2520717123.
     PubMed         Abstract available
     
     
106. ABDULKAREEM NM, Jiang Y, Qi Y, Liu X, et al
     Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.
     Proc Natl Acad Sci U S A. 2026;123:e2513742123.
     PubMed         Abstract available
     
     

     
     Radiology

107. LO GULLO R, Surovitsky M, Kim D, Sevilimedu V, et al
     Abbreviated MRI for the Evaluation of Treatment Response in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
     Radiology. 2026;319:e252413.
     PubMed         Abstract available
     
     

     
     Semin Oncol

108. VAGNET A, Ferraj M, Dobi E, Valnet Rabier MB, et al
     Pregnancy during pembrolizumab therapy for triple-negative breast cancer with onset of congenital hypothyroidism: Case report, literature review, and caution for clinical practice.
     Semin Oncol. 2026;53:152486.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum